These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9187614)

  • 1. Administration of amphotericin B in lipid emulsion.
    O'Neil MG; Lapointe M
    Crit Care Med; 1997 May; 25(5):892-3; author reply 893-4. PubMed ID: 9187614
    [No Abstract]   [Full Text] [Related]  

  • 2. Administration of amphotericin B in lipid emulsion.
    Devlin J; Bailey E; Zarowitz B
    Crit Care Med; 1997 May; 25(5):892; author reply 893-4. PubMed ID: 9187613
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
    Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
    J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
    Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
    Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
    Caillot D; Casasnovas O; Solary E; Chavanet P; Bonnotte B; Reny G; Entezam F; Lopez J; Bonnin A; Guy H
    J Antimicrob Chemother; 1993 Jan; 31(1):161-9. PubMed ID: 8444659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients.
    Macedo MC; Dulley FL; Ostronoff M; Machado CM; Zambon E; Matsumoto C; Dorlhiac-Llaccer P; Chamone DF
    Clin Infect Dis; 1994 Aug; 19(2):366-7. PubMed ID: 7986930
    [No Abstract]   [Full Text] [Related]  

  • 9. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
    Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
    BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
    Kirsh R; Goldstein R; Tarloff J; Parris D; Hook J; Hanna N; Bugelski P; Poste G
    J Infect Dis; 1988 Nov; 158(5):1065-70. PubMed ID: 3183418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B infused in 20% lipid emulsion.
    Ryan KA
    J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
    Souza LC; Campa A
    J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion.
    Lopez RM; Ayestaran A; Pou L; Montoro JB; Hernandez M; Caragol I
    Am J Health Syst Pharm; 1996 Nov; 53(22):2724-7. PubMed ID: 8931814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphotericin B in fat emulsion.
    Kintzel PE
    Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
    [No Abstract]   [Full Text] [Related]  

  • 16. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B formulated in a lipid emulsion.
    Cleary JD
    Ann Pharmacother; 1996 Apr; 30(4):409-12. PubMed ID: 8729899
    [No Abstract]   [Full Text] [Related]  

  • 18. Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies. Haematology-Microbiology Group.
    Laverdière M; Habel F; Weiss K; Delorme J; Dubois G; Gagnon N; Bélanger R
    J Antimicrob Chemother; 1997 Dec; 40(6):910-2. PubMed ID: 9462450
    [No Abstract]   [Full Text] [Related]  

  • 19. Fatal fat embolism following amphotericin B lipid complex injection.
    Tolentino LF; Tsai SF; Witt MD; French SW
    Exp Mol Pathol; 2004 Dec; 77(3):246-8. PubMed ID: 15507243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.
    Owens D; Fleming RA; Restino MS; Cruz JM; Hurd DD
    Am J Health Syst Pharm; 1997 Mar; 54(6):683-6. PubMed ID: 9075499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.